Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription 25.11.2024 2 Ann Surg Oncol 1 Ann Thorac Surg 1 Arch Bronconeumol 4 BMC Cancer 1 Cancer Chemother Pharmacol 2 Cancer Lett 2 Clin Cancer Res 5 Clin Lung Cancer 2 Eur J Cancer 3 Eur J Cardiothorac Surg 1 Genes Chromosomes Cancer 2 Int J Cancer 3 J Cancer Res Clin Oncol 3 J Clin Oncol 2 J Natl Cancer Inst 1 J Surg Oncol 2 J Thorac Oncol 5 Lung Cancer 1 Mol Cancer Ther 2 Nat Med 1 Oncogene 2 Oncologist 6 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. LIU W, Yue D, Zhang B
   ASO Author Reflections: The Candidate Biomarkers for Predicting Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2024 Nov 15. doi: 10.1245/s10434-024-16150.
   PubMed        
   
   
2. UEDA D, Mimae T, Okada M
   ASO Author Reflections: Surgical Procedures for Early-Stage Lung Cancer Patients with Low Muscle Mass.
   Ann Surg Oncol. 2024 Nov 15. doi: 10.1245/s10434-024-16481.
   PubMed        
   
   

   
   Ann Thorac Surg

3. AL-THANI S, Nasar A, Villena-Vargas J, Chow O, et al
   Does High Standard Uptake Value on Positron Emission Tomography Preclude Sublobar Resection in Stage IA Non-Small Cell Lung Cancer
   Ann Thorac Surg. 2024 Nov 13:S0003-4975(24)00957.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

4. GONZALEZ-CASTRO S, Cadavid-Fernandez N, Gorospe Sarasua L
   Silicone-induced Lymphadenopathy Mimicking Metastatic Lung Cancer.
   Arch Bronconeumol. 2024 Nov 2:S0300-2896(24)00416.
   PubMed        
   
   

   
   BMC Cancer

5. BADE BC, Gan G, Li F, Lu L, et al
   Correction: Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study.
   BMC Cancer. 2024;24:1409.
   PubMed        
   
   
6. RASMUSSEN TR, Gouliaev A, Jakobsen E, Hjorthaug K, et al
   Impact of multidisciplinary team discrepancies on comparative lung cancer outcome analyses and treatment equality.
   BMC Cancer. 2024;24:1423.
   PubMed         Abstract available
   
   
7. KOYAMA J, Morise M, Furukawa T, Oyama S, et al
   Artificial intelligence-based personalized survival prediction using clinical and radiomics features in patients with advanced non-small cell lung cancer.
   BMC Cancer. 2024;24:1417.
   PubMed         Abstract available
   
   
8. LEI S, Tian L, Yang L, Yang Y, et al
   Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review.
   BMC Cancer. 2024;24:1427.
   PubMed         Abstract available
   
   

   
   Cancer Chemother Pharmacol

9. DE ROUW N, Beunders R, Hartmann O, Schulte J, et al
   A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed.
   Cancer Chemother Pharmacol. 2024;94:799-806.
   PubMed         Abstract available
   
   

   
   Cancer Lett

10. SUAY G, Garcia-Canaveras JC, Aparisi F, Garcia J, et al
    Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations.
    Cancer Lett. 2024;606:217317.
    PubMed         Abstract available
    
    
11. NERLAKANTI N, McGuire JJ, Bishop RT, Nasr MM, et al
    Histone deacetylase upregulation of neuropilin-1 in osteosarcoma is essential for pulmonary metastasis.
    Cancer Lett. 2024;606:217302.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

12. SOO RA, Dafni U, Han JY, Cho BC, et al
    ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
    Clin Cancer Res. 2024;30:5180-5191.
    PubMed         Abstract available
    
    
13. ALTAN M, Lopes G, Hiltermann TJN, Govindan R, et al
    Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1591.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

14. JO Y, Puri S, Haaland B, Coletta AM, et al
    Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2024 Oct 9:S1525-7304(24)00205.
    PubMed         Abstract available
    
    
15. QASIM R, Riaz Z
    Comment on "Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-Small-Cell Lung Cancer".
    Clin Lung Cancer. 2024 Oct 25:S1525-7304(24)00225.
    PubMed        
    
    
16. MATHIOT L, Raimbourg J
    Comment on ;;Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung Cancer''.
    Clin Lung Cancer. 2024 Oct 28:S1525-7304(24)00224.
    PubMed        
    
    
17. SEITLINGER J, Patel D, Meng A, Bulgarelli-Maqueda L, et al
    Perioperative Outcomes of Neoadjuvant Therapy in Resectable Lung Cancer Patients With Endobronchial Disease in the Era of Personalized Medicine.
    Clin Lung Cancer. 2024 Oct 16:S1525-7304(24)00208.
    PubMed         Abstract available
    
    
18. LEI F, Sekkath-Veedu J, Huang B, Chen Q, et al
    Inclusion of Surgery in Multimodality Treatment is Predictive of Better Survival in Stage IIIA Non-small Cell Lung Cancer: An Inverse Probability Treatment-Weighting Analysis.
    Clin Lung Cancer. 2024 Oct 18:S1525-7304(24)00221.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

19. PATEL AJ, Hemead H, Law J, Wali A, et al
    Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): A systematic review and meta-analysis of randomised trials.
    Eur J Cancer. 2024;214:115118.
    PubMed         Abstract available
    
    
20. ALSHAMMARI A, Patel A, Boyle M, Proli C, et al
    Prevalence of invasive lung cancer in pure ground glass nodules less than 30 mm: A systematic review.
    Eur J Cancer. 2024;213:115116.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

21. GALLINA FT, Cecere FL, Taje R, Bertolaccini L, et al
    Predictive and prognostic factors in patients with anaplastic lymphoma kinase rearranged early-stage lung adenocarcinoma.
    Eur J Cardiothorac Surg. 2024;66:ezae406.
    PubMed         Abstract available
    
    
22. BRUNELLI A, Antonoff MB, Petersen RH, Stiles BM, et al
    Surgeon preferences for self-treatment in locally advanced non-small cell lung cancer: Would we practice what we preach?
    Eur J Cardiothorac Surg. 2024;66:ezae344.
    PubMed        
    
    
23. LUO X, Hayanga JWA, Mehaffey JH, Lamb J, et al
    Clinical stage IA non-small cell lung cancer with occult pathologic N1 and N2 disease after segmentectomy: does a completion lobectomy justify?
    Eur J Cardiothorac Surg. 2024 Nov 19:ezae415. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

24. SHARPE B, Green DC, Tafe LJ, Wasp GT, et al
    An Inflammatory Myofibroblastic Tumor With a Novel ALK(V1180L) Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors.
    Genes Chromosomes Cancer. 2024;63:e70012.
    PubMed         Abstract available
    
    

    
    Int J Cancer

25. BURUS T, Patel MI, Christian WJ, Huang B, et al
    Sex-based differences in histologic lung cancer incidence trends in the United States, 2005-2019.
    Int J Cancer. 2024 Nov 21. doi: 10.1002/ijc.35268.
    PubMed         Abstract available
    
    
26. KANZAKI R, Reid S, Bolivar P, Sjolund J, et al
    FHL2 expression by cancer-associated fibroblasts promotes metastasis and angiogenesis in lung adenocarcinoma.
    Int J Cancer. 2025;156:431-446.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

27. IBRULI O, Rose F, Beleggia F, Schmitt A, et al
    A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade.
    J Cancer Res Clin Oncol. 2024;150:496.
    PubMed         Abstract available
    
    
28. LI S, Yuan T, Yuan J, Zhu B, et al
    Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy.
    J Cancer Res Clin Oncol. 2024;150:501.
    PubMed         Abstract available
    
    
29. RISCHKE N, Kanbach J, Haug U
    Age differences in the treatment of lung cancer-a cohort study among 42,000 patients from Germany.
    J Cancer Res Clin Oncol. 2024;150:503.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

30. KALEMKERIAN GP, Khurshid H, Ismaila N
    Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2024 Nov 20:JCO2402245. doi: 10.1200/JCO-24-02245.
    PubMed         Abstract available
    
    
31. NOGUCHI M, Shindo Y, Wakabayashi K, Koide Y, et al
    Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2401876. doi: 10.1200/JCO-24-01876.
    PubMed        
    
    
32. RUSTHOVEN CG, Miao E, Boe LA, Pike LRG, et al
    Reply to: Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2402129. doi: 10.1200/JCO-24-02129.
    PubMed        
    
    

    
    J Natl Cancer Inst

33. GOMEZ SL, DeRouen M, Chen MS Jr, Wakelee H, et al
    Elevated risk of lung cancer among asian American females who have never smoked: an emerging cancer disparity.
    J Natl Cancer Inst. 2024 Nov 20:djae299. doi: 10.1093.
    PubMed         Abstract available
    
    
34. SMITH RJ JR, Zollo R, Kalvapudi S, Vedire Y, et al
    Obesity-Specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin.
    J Natl Cancer Inst. 2024 Nov 19:djae295. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

35. DE ALMEIDA DPA, Malta MFB, Cardoso WM, Leite ALDS, et al
    Metastatic benign leiomyoma: A case report of an uncommon presentation.
    J Surg Oncol. 2024;130:951-954.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

36. ZHAO S, Zhou H, Yang N, Wang Z, et al
    Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial.
    J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02445.
    PubMed         Abstract available
    
    
37. LEVY A, Rusthoven CG, Brown PD, Le Pechoux C, et al
    PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era.
    J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02446.
    PubMed         Abstract available
    
    

    
    Lung Cancer

38. YU Y, Fan Y, Dong X, Li J, et al
    Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison.
    Lung Cancer. 2024;198:108018.
    PubMed         Abstract available
    
    
39. UCHIBORI A, Okada S, Shimomura M, Furuya T, et al
    Clinical impact of preoperative sarcopenia and immunonutritional impairment on postoperative outcomes in non-small cell lung cancer surgery.
    Lung Cancer. 2024;198:108004.
    PubMed         Abstract available
    
    
40. AKAMATSU H, Koh Y, Nishio M, Goto Y, et al
    Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.
    Lung Cancer. 2024;198:108017.
    PubMed         Abstract available
    
    
41. YU Z, Zou J, Xu F
    The molecular subtypes of small cell lung cancer defined by key transcription factors and their clinical significance.
    Lung Cancer. 2024;198:108033.
    PubMed         Abstract available
    
    
42. OSATAPHAN S, Awidi M, Jan YJ, Gunturu K, et al
    Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
    Lung Cancer. 2024;198:108023.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

43. OH MS, Dumitras C, Salehi-Rad R, Tran LM, et al
    Characteristics of a CCL21-gene modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer.
    Mol Cancer Ther. 2024 Nov 19. doi: 10.1158/1535-7163.MCT-24-0435.
    PubMed         Abstract available
    
    

    
    Nat Med

44. WANG C, Shao J, He Y, Wu J, et al
    Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography.
    Nat Med. 2024;30:3184-3195.
    PubMed         Abstract available
    
    
45. ALBAN TJ, Riaz N, Parthasarathy P, Makarov V, et al
    Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.
    Nat Med. 2024;30:3209-3222.
    PubMed         Abstract available
    
    

    
    Oncogene

46. CHEN T, Ashwood LM, Kondrashova O, Strasser A, et al
    Breathing new insights into the role of mutant p53 in lung cancer.
    Oncogene. 2024 Nov 20. doi: 10.1038/s41388-024-03219.
    PubMed         Abstract available
    
    

    
    Oncologist

47. NAIDOO J, Johnson DB, Doran C, Wang Y, et al
    Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors.
    Oncologist. 2024 Nov 20:oyae318. doi: 10.1093.
    PubMed         Abstract available
    
    
48. SADAGOPAN N, Komlodi-Pasztor E, Veytsman I
    Immunotherapy benefits for large brain metastases in non-small cell lung cancer.
    Oncologist. 2024 Nov 15:oyae314. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

49. DONG Y, Li S, Che G
    Is it safe and feasible to use multi-lateral-pores drainage strategy after video-assisted thoracoscopic surgery?
    PLoS One. 2024;19:e0313176.
    PubMed         Abstract available
    
    
50. BONERT M, Schittenhelm J, Begum H, Lu JQ, et al
    Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers.
    PLoS One. 2024;19:e0314205.
    PubMed         Abstract available
    
    
51. ZHANG E, Feng X, Liu F, Zhang P, et al
    Correction: Roles of PI3K/Akt and c-Jun Signaling Pathways in Human Papillomavirus Type 16 Oncoprotein-Induced HIF-1alpha, VEGF, and IL-8 Expression and In Vitro Angiogenesis in Non-Small Cell Lung Cancer Cells.
    PLoS One. 2024;19:e0314378.
    PubMed         Abstract available
    
    
52. YADAV DP, Sharma B, Webber JL, Mehbodniya A, et al
    EDTNet: A spatial aware attention-based transformer for the pulmonary nodule segmentation.
    PLoS One. 2024;19:e0311080.
    PubMed         Abstract available
    
    
53. GUIBIN D, Xiaolan S, Wei Z, Xiaoli L, et al
    Prediction of iodine-125 seed implantation efficacy in lung cancer using an enhanced CT-based nomogram model.
    PLoS One. 2024;19:e0313570.
    PubMed         Abstract available
    
    
54. WANG S, Yan H, Wen J, Zhou Z, et al
    Risk factors for conversion to thoracotomy in patients with lung cancer undergoing video-assisted thoracoscopic surgery: A meta-analysis.
    PLoS One. 2024;19:e0313236.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.